对我们覆盖范围的美国临床肿瘤学会（ASCO）摘要的初步解读
摩根士丹利·2025-05-23 10:50
May 23, 2025 05:03 AM GMT Biotechnology | North America 1st Take on ASCO Abstracts for Our Coverage We provide a first look at key ASCO abstracts for our coverage. For GMAB, initial PhI/II Rina-S EC efficacy is competitive, and we await further context on the Gr5 event. For LEGN, data for Carvykti remain impressive and DLL3 & Claudin 18.2 updates present an intriguing start to the pipeline. Key Takeaways Genmab (GMAB): Abstract 3039 - Rinatabart sesutecan (Rina-S) for patients with advanced endometrial canc ...